Armata Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 21, 2024. This is an annual report, not a standalone fourth-quarter report.
Business context
Armata is a clinical-stage biotechnology company developing bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections. Its lead programs are AP-PA02 for chronic Pseudomonas aeruginosa lung infections and AP-SA02 for Staphylococcus aureus bacteremia. The company has no commercial product revenue and depends on grants and financing to fund development.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Grant revenue | $4.5 million | $5.5 million |
| Research and development expense | $33.8 million | $35.0 million |
| General and administrative expense | $11.6 million | $7.4 million |
| Operating loss | $40.9 million | $36.9 million |
| Net loss | $69.0 million | $36.9 million |
| Net loss per share, basic and diluted | $1.91 | $1.08 |
| Net cash used in operating activities | $47.4 million | $32.5 million |
| Net cash used in investing activities | $8.1 million | $2.2 million |
| Net cash provided by financing activities | $54.0 million | $44.0 million |
- At December 31, 2023, cash and cash equivalents were $13.5 million, restricted cash was $5.7 million, and current assets totaled $19.2 million. Total liabilities were $130.4 million; stockholders’ equity was a deficit of $32.1 million.
- Year-end debt included convertible debt carried at fair value of $58.6 million and long-term debt of $23.7 million. The company also had substantial lease obligations: $38.1 million present value of operating lease obligations.
- Debt financing in 2023 included a $30 million convertible loan at 8% and a $25 million secured loan at 14%, both due January 2025. A subsequent $35 million secured loan from principal stockholder Innoviva was received in March 2024, bears 14% interest, and matures June 2025.
- The filing reports substantial doubt about the company’s ability to continue as a going concern. Management stated that year-end cash plus the March 2024 loan would not fund operations for the 12 months following the financial statements; further financing is required.
- Gross margin is not a meaningful measure for this development-stage company; the filing reports grant revenue and operating expenses rather than commercial product sales.
Material changes versus 2022
- Net loss increased 87% to $69.0 million, driven largely by $21.8 million of noncash loss from changes in the fair value of convertible debt, a $3.9 million debt-extinguishment loss, and $2.6 million of interest expense. These debt-related charges were not reported in 2022.
- Operating loss increased 10.7%. G&A expense rose $4.2 million, primarily from higher legal, accounting, and consulting costs; R&D expense declined $1.2 million.
- Operating cash use rose by $14.9 million. The company raised $54.0 million through debt financing in 2023, compared with $44.0 million from common-stock sales in 2022.
- Cash and cash equivalents declined from $14.9 million to $13.5 million. Property and equipment increased to $12.6 million, reflecting investment in the planned manufacturing facility.
Outlook, development, and risks
- Management aims to complete the AP-PA02 Phase 2 Tailwind study in 2024 and use results to support a potential pivotal trial in 2025. The AP-SA02 diSArm study is ongoing; a definitive efficacy trial is targeted for 2025. These are plans, not assured outcomes.
- AP-PA02’s completed cystic-fibrosis Phase 1b/2a study showed tolerability similar to placebo, lung delivery with minimal systemic exposure, and a suggested reduction in sputum bacterial load. The filing describes these findings as early evidence; later-stage efficacy is unproven.
- The company is revising plans for an AP-SA02 study to include prosthetic joint and wound infections. Initiation depends on funding and results from the bacteremia program.
- The new Los Angeles manufacturing space was expected to be completed in the second half of 2024, with manufacturing transition planned. The company expects $5.4 million of additional construction-related expenses by mid-2024 and is seeking a subtenant for its Marina del Rey facility.
- Key risks include continuing losses and financing needs; clinical, regulatory, and manufacturing uncertainty; patient enrollment and third-party execution; and possible dilution or constraints from secured debt. The Innoviva loans are secured by substantially all company assets. Innoviva owned approximately 69.5% of outstanding shares at year-end, and also holds warrants and convertible-debt rights that could increase its ownership or dilute other shareholders.
- The 2023 convertible-debt fair-value loss relies on significant estimates and assumptions. The filing reports no material legal proceedings and states that management’s disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control.
Most important facts for investors to verify
- Current cash runway, spending plans, and whether additional financing has been secured on acceptable terms.
- Terms, carrying values, repayment obligations, collateral, and potential conversion or dilution effects of Innoviva’s loans and warrants.
- Enrollment, completion timing, safety, and efficacy data for Tailwind and diSArm, and whether the planned 2025 pivotal trials remain feasible.
- Completion, inspection, cost, and operational readiness of the Los Angeles cGMP facility, plus the outcome of efforts to sublease Marina del Rey.
- Grant funding availability and obligations, including the MTEC award’s stated term through October 2024 and any commercial or licensing-related payments.